Acute leukemia type M5, also known as acute monocytic leukemia, is a type of acute myeloid leukemia. The survival rate of acute leukemia M5 is divided into three-year survival rate, five-year survival rate and long-term survival rate. Generally, the three-year survival rate of type M5 is about 80%, the five-year survival rate is about 50% and the long-term survival rate is between 20% and 30%. Because the most conventional treatment for acute monocytic leukemia is chemotherapy, commonly used chemotherapy drugs include erythromycin, cytarabine, desmethoxyzolomycin, and so on. To completely cure acute leukemia M5, the most effective method is still to do allogeneic hematopoietic stem cell transplantation, which generally has a success rate of about 90%, and about 30%-50% of patients will relapse after success. Therefore, the survival rate of acute leukemia M5 is still relatively low.